AnaptysBio (ANAB) said Wednesday that a phase 2b trial of its investigational drug rosnilimab to treat moderate-to-severe rheumatoid arthritis achieved its primary and secondary endpoints.
Patients in the study received either 100 milligram or 400 milligram doses of rosnilimab every four weeks, 600 milligrams every two weeks, or placebo, the company said.
The trial achieved its primary endpoint of a change from baseline for all three doses vs. placebo at week 12 and showed that the drug was safe and well-tolerated, the company said.
AnaptysBio shares were 23% higher in premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。